IRAK4 and hidradenitis suppurativa: Indazole-based IRAK4 inhibitors have also recentlybeen described by Zhejiang Hisun Pharmceutical Co. Ltd.24 Finally, Kymera advanced IRAK4 degrader KT-474to Phase 2 clinical trials for the treatment of atopic dermatitisand hidradenitis suppurativa (ClinicalTrials.gov Identifiers: NCT06058156and NCT06028230, studies initiated by collaborator Sanofi).